Evidence map›Paper›PMID 39450669›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients.

Sergio Escamilla, Raquel Badillos, Joan X Comella, Montse Solé, Isabel Pérez-Otaño, Jose V Sánchez Mut, Javier Sáez-Valero, Inmaculada Cuchillo-Ibáñez

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Pooled it
  2. Article
  3. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. The GluN3-containing NMDA receptors.Channels (Austin, Tex.) · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Future Perspectives of NMDAR in CNS Disorders.Molecules (Basel, Switzerland) · 2025
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sergio EscamillaInstituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Sant Joan d'Alacant, Spain.
Raquel BadillosCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Ciberned), Madrid, Spain.
Joan X ComellaCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Ciberned), Madrid, Spain.
Montse SoléCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Ciberned), Madrid, Spain.
Isabel Pérez-OtañoInstituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Sant Joan d'Alacant, Spain.
Jose V Sánchez MutInstituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Sant Joan d'Alacant, Spain.
Javier Sáez-ValeroInstituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Sant Joan d'Alacant, Spain.
Inmaculada Cuchillo-IbáñezInstituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Sant Joan d'Alacant, Spain.ORCID 0000-0002-3689-5518

Funding

Centro de Excelencia Severo Ochoa, Agencia Estatal de Investigación CEX2021-001165-SCIBERNED (Instituto de Salud Carlos III)Direcció General de Ciència i Investigació, Generalitat Valenciana AICO/2021/308Fondo de Investigaciones Sanitarias, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER "Investing in your future PI22/01329Instituto de Investigación Sanitaria y Biomédica de Alicante (Isabial)Programa Investigo, Conselleria de Innovación, Universidades, Investigación y Sociedad Digital, , Generalitat Valenciana INVEST-2023-157
6 · The paper itself

Abstract

backgroundSynaptic and extrasynaptic distribution of N-methyl-D-aspartate receptors (NMDARs) has not been addressed in the brain from Alzheimer´s disease (AD) subjects, despite their contribution to neurodegeneration.

methodsWe have developed a protocol to isolate synaptic and extrasynaptic membranes from controls and AD frontal cortex. We characterized the distribution of the NMDAR subunits GluN2B, GluN2A, GluN1, and GluN3A, as well as post-translational modifications, such as phosphorylation and glycosylation.

resultsLower levels of synaptic GluN2B and GluN2A were found in AD fractions, while extrasynaptic GluN2B and GluN1 levels were significantly higher; GluN3A distribution remained unaffected in AD. We also identified different glycoforms of GluN2B and GluN2A in extrasynaptic membranes. Synaptic Tyr1472 GluN2B phosphorylation was significantly lower in AD fractions. DISCUSSION: Reduction of synaptic NMDAR subunits, particularly for GluN2B, is likely to contribute to synaptic transmission failure in AD. Additionally, the increment of extrasynaptic NMDAR subunits could favor the activation of excitotoxicity in AD. HIGHLIGHTS: New protocol to isolate synaptic and extrasynaptic membranes from the human cortex. Low GluN2B and GluN2A levels in Alzheimer´s disease (AD) synaptic membranes. High GluN2B and GluN1 levels in AD extrasynaptic membranes. Specific glycoforms of extrasynaptic GluN2B and GluN2A. Low phosphorylation at Tyr1472 in synaptic GluN2B in AD.

Indexed as

Alzheimer DiseaseReceptors, N-Methyl-D-AspartateSynapsesAgedAged, 80 and overCerebral CortexFemaleFrontal LobeHumansMaleMiddle AgedPhosphorylationProtein Processing, Post-TranslationalReceptors, N-Methyl-D-AspartateAlzheimer´s diseaseextrasynapticGluN1GluN2AGluN2BGluN3AhumanNMDATyr1336Tyr1472

Identifiers

PMID39450669
PMCPMC11667538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.